Lakefront Biotherapeutics NV GLPGF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -48.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -48.98% |
| Cost of Revenue | -- | -- | -- | -- | 8.71% |
| Gross Profit | -- | -- | -- | -- | -395.13% |
| SG&A Expenses | -- | -- | -- | -- | -38.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 23.73% |
| Total Operating Expenses | -- | -- | -- | -- | -6.06% |
| Operating Income | -- | -- | -- | -- | -210.69% |
| Income Before Tax | -- | -- | -- | -- | -726.53% |
| Income Tax Expenses | -- | -- | -- | -- | 22.00% |
| Earnings from Continuing Operations | -- | -- | -- | -- | -683.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -99.21% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | -202.24% |
| EBIT | -- | -- | -- | -- | -210.69% |
| EBITDA | -- | -- | -- | -- | -403.73% |
| EPS Basic | -- | -- | -- | -- | -202.23% |
| Normalized Basic EPS | -- | -- | -- | -- | -5,905.76% |
| EPS Diluted | -- | -- | -- | -- | -202.36% |
| Normalized Diluted EPS | -- | -- | -- | -- | -6,091.99% |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -0.14% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |